<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DECAVAC- clostridium tetani toxoid antigen (formaldehyde inactivated) and corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) suspension </strong><br>Sanofi Pasteur Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use DECAVAC (<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoids Adsorbed) safely and effectively. See full prescribing information for DECAVAC<span class="Sup">®</span>.<br><br> DECAVAC<span class="Sup">®</span> (<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoids Adsorbed)<br> Suspension for Intramuscular Injection<br> Initial U.S. Approval: 1955</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="50%">
<col align="left" valign="top" width="75%">
<col align="right" valign="top" width="25%">
<tbody class="Headless"><tr class="First Last Toprule">
<td align="left">
<span class="Bold">Warnings and Precautions (</span><a href="#S5.2">5.2</a><span class="Bold">)</span>
</td>
<td align="right"><span class="Bold">[01/2011]</span></td>
</tr></tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">DECAVAC is a vaccine indicated for active immunization for the prevention of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span>. DECAVAC is approved for use in persons 7 years of age and older. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Each 0.5 mL dose should be administered intramuscularly. (<a href="#S2.1">2.1</a>)</li>
<li>Primary immunization consists of 3 doses. The first two doses are administered at least 4 weeks apart and the third dose is administered at least 6 months after the second dose. (<a href="#S2.1">2.1</a>)</li>
<li>Routine booster immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> is recommended at 11-12 years of age and every 10 years thereafter. (<a href="#S2.1">2.1</a>)</li>
</ul></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Suspension for injection supplied in 0.5 mL single-dose vials or syringes. (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (eg, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) after a previous dose of DECAVAC or any other <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid or <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid containing vaccine or any other component of this vaccine. (<a href="#S4.1">4.1</a>)</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>The tip caps of the prefilled syringes may contain natural rubber latex which may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> in latex sensitive individuals. (<a href="#S5.2">5.2</a>)</li>
<li> More frequent administration of DECAVAC than described in Dosage and Administration may be associated with increased incidence and severity of adverse reactions. (<a href="#S5.3">5.3</a>)</li>
<li> Persons who experienced an Arthus-type <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> following a prior dose of a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine should not receive DECAVAC less than 10 years since the last dose of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine, even for <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> prophylaxis as part of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> management. (<a href="#S5.4">5.4</a>)</li>
<li> If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid, the risk for Guillain-Barré syndrome may be increased following DECAVAC. (<a href="#S5.5">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li> The most frequent solicited <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span> following DECAVAC was <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, reported in 71% of adolescents 11-17 years of age and in 63% of adults 18-64 years of age. (<a href="#S6.1">6.1</a>)</li>
<li> The most frequent solicited systemic adverse event following DECAVAC was <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, reported in 40% of adolescents 11-17 years of age and in 34% of adults 18-64 years of age. (<a href="#S6.1">6.1</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4319319" conceptname="Injection site edema">Injection site swelling</span>, injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, body <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">ache</span> or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> also were reported commonly (≥10%) in both age groups; <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and sore and <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">swollen joints</span> were reported commonly (≥ 10%) in adolescents. (<a href="#S6.1">6.1</a>)</li>
</ul>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sanofi Pasteur Inc. at 1-800-822-2463 (1-800-VACCINE) or VAERS at 1-800-822-7967 or </span>www.vaers.hhs.gov. </p>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li> No safety and immunogenicity data are available on concomitant administration of DECAVAC with other US licensed vaccines. (<a href="#S7.1">7.1</a>)</li>
<li> Immunosuppressive therapies may reduce the immune response to DECAVAC. (<a href="#S7.2">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1.	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2.	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1.	Dosage and Schedule</a></h2>
<h2><a href="#section-2.2" class="toc">2.2.	Administration</a></h2>
<h1><a href="#section-3" class="toc">3.	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4.	CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1.	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-5" class="toc">5.	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1.	Management of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Acute Allergic Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2.	Latex</a></h2>
<h2><a href="#section-5.3" class="toc">5.3.	Frequency of Administration</a></h2>
<h2><a href="#section-5.4" class="toc">5.4.	Arthus Reactions</a></h2>
<h2><a href="#section-5.5" class="toc">5.5. Guillain-Barré Syndrome and Brachial <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">Neuritis</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6.	Limitations of Vaccine Effectiveness</a></h2>
<h2><a href="#section-5.7" class="toc">5.7.	Altered Immunocompetence</a></h2>
<h1><a href="#section-6" class="toc">6.	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1.	Data from Clinical Studies</a></h2>
<h2><a href="#section-6.2" class="toc">6.2.	Primary Immunization</a></h2>
<h2><a href="#section-6.3" class="toc">6.3.	Booster Immunization</a></h2>
<h2><a href="#section-6.4" class="toc">6.4.	Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7.	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1.	Concomitant Administration with Other Vaccines</a></h2>
<h2><a href="#section-7.2" class="toc">7.2.	Immunosuppressive Treatments</a></h2>
<h2><a href="#section-7.3" class="toc">7.3.	<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Immune Globulin (Human)</a></h2>
<h1><a href="#section-8" class="toc">8.	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1.	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3.	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4.	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5.	Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">11.	DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12.	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1.	<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span></a></h2>
<h2><a href="#section-10.2" class="toc">12.2.	<span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span></a></h2>
<h1><a href="#section-11" class="toc">13.	NON-CLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1.	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14.	CLINICAL STUDIES</a></h1>
<h2><a href="#section-12.1" class="toc">14.1.	Primary Immunization</a></h2>
<h2><a href="#section-12.2" class="toc">14.2.	Booster Immunization</a></h2>
<h1><a href="#section-13" class="toc">15.	REFERENCES</a></h1>
<h1><a href="#section-14" class="toc">16.	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1.	How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2.	Storage and Handling</a></h2>
<h1><a href="#section-15" class="toc">17.	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1.	INDICATIONS AND USAGE</h1>
<p class="First">DECAVAC<span class="Sup">®</span> is a vaccine indicated for active immunization for the prevention of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span>. DECAVAC vaccine is approved for use in persons 7 years of age and older.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2.	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1.	Dosage and Schedule</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Bold">Primary Immunization</span></p>
<p>DECAVAC vaccine may be used in persons 7 years of age and older who have not been immunized previously against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> or who have begun a primary immunization series but did not complete it. The primary immunization series consists of three 0.5 mL doses. The first two doses are administered at least 4 weeks apart and the third dose is administered at least 6 months after the second dose.</p>
<p>DECAVAC vaccine may be used to complete the primary immunization series for <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> in persons 7 years of age or older who have received one or two doses of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids and <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (whole-cell DTP), <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (DTaP) and/or <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed (DT). However, the safety and efficacy of DECAVAC vaccine in such regimens have not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<p class="First"><span class="Bold">Routine Booster Immunization</span></p>
<p>DECAVAC vaccine may be used for routine booster immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> in persons 7 years of age and older who have completed primary immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span>. Routine booster immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> is recommended in children 11-12 years of age and every 10 years thereafter. (1)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.3"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Prophylaxis in <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Management</span></p>
<p>For active <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> immunization in <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> management of patients 7 years of age and older, a preparation containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoids is preferred instead of single-antigen <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid to enhance <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> protection. (2) DECAVAC vaccine is approved for <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> management of patients 7 years of age and older.</p>
<p>The need for active immunization with a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing preparation, with or without <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Immune Globulin (TIG) (Human) depends on both the condition of the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> and the patient's vaccination history (Table 1).</p>
<p>When indicated, TIG (Human) should be administered using a separate needle and syringe at a different anatomic site, according to the manufacturer's package insert. If a contraindication to using a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine exists in a person who has not completed <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> primary immunization and other than a clean, minor <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> is sustained, only passive immunization with TIG (Human) should be given. (2)</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: Guide to Use of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoids Adsorbed (Td) and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Immune Globulin (TIG) (Human) for <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Prophylaxis in Routine <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Management for Persons 7 Years of Age and Older</span></caption>
<col align="center" valign="top" width="32%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="2">History of Adsorbed <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid (doses)</th>
<th class="Botrule Rrule" align="center" colspan="2">Clean, Minor <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wounds</span></th>
<th class="Botrule Rrule" align="center" colspan="2">All Other <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wounds</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">Td</th>
<th class="Rrule" align="center">TIG</th>
<th class="Rrule" align="center">Td</th>
<th class="Rrule" align="center">TIG</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Such as, but not limited to, <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> contaminated with dirt, feces, soil, and saliva; puncture <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>; avulsions; and <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> resulting from missiles, crushing, <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, and <span class="product-label-link" type="condition" conceptid="441487" conceptname="Frostbite">frostbite</span>.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>If only three doses of fluid <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid have been received, then a fourth dose of toxoid, preferably, an adsorbed toxoid should be given.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Yes, if ≥10 years since the last <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine dose.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Yes, if ≥5 years since the last <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine dose. (More frequent boosters are not needed and can accentuate side effects.)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Unknown or &lt;three</span></td>
<td class="Rrule" align="left">Yes</td>
<td class="Rrule" align="left">No</td>
<td class="Rrule" align="left">Yes</td>
<td class="Rrule" align="left">Yes</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">
<span class="Bold">≥three</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="left">No<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="left">No</td>
<td class="Rrule" align="left">No<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Rrule" align="left">No</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.4"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Prophylaxis for Case Contacts</span></p>
<p>DECAVAC vaccine may be used for post-exposure <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> prophylaxis in persons 7 years of age and older who have not completed primary vaccination, whose vaccination status is unknown, or who have not been vaccinated with <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid within the previous 5 years. Consult ACIP recommendations for additional interventions for post-exposure <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> prophylaxis. (2)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2.	Administration</h2>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If these conditions exist, DECAVAC vaccine should not be administered.</p>
<p>DECAVAC vaccine, after <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, is a turbid liquid, whitish-gray in color.</p>
<p>For DECAVAC vaccine supplied in vials, shake the vial well before withdrawing the dose. Discard vial if DECAVAC vaccine cannot be resuspended.</p>
<p>For DECAVAC vaccine supplied in syringes, shake the syringe well before administering the dose. Discard syringe if DECAVAC vaccine cannot be resuspended.</p>
<p>Inject 0.5 mL intramuscularly. The preferred site is the deltoid muscle. DECAVAC vaccine should not be injected into the gluteal area or areas where there may be a major nerve trunk.</p>
<p>Do not administer DECAVAC vaccine intravenously or subcutaneously.</p>
<p>DECAVAC vaccine should not be combined through reconstitution or mixed with any other vaccine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3.	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">DECAVAC vaccine is a sterile suspension for injection available in 0.5 mL single-dose vials or syringes.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4.	CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1.	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">A severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (eg, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) after a previous dose of DECAVAC vaccine or any other <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid or <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid containing vaccine or any other component of this vaccine is a contraindication to administration of DECAVAC vaccine. [See<span class="Italics"><a href="#S11"> Description (11)</a>.</span>] Because of uncertainty as to which component of the vaccine may be responsible, no further vaccination with <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> or <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> components should be carried out. Alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5.	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1.	Management of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Acute Allergic Reactions</span></h2>
<p class="First">Epinephrine injection (1:1000) and other appropriate agents and equipment must be immediately available should an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">acute anaphylactic reaction</span> occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2.	Latex</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The tip caps of the DECAVAC prefilled syringes may contain natural rubber latex, which may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> in latex-sensitive individuals.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3.	Frequency of Administration</h2>
<p class="First">More frequent administration of DECAVAC vaccine than described in Dosage and Administration [see<span class="Italics"><a href="#S2.1"> Dosage and Administration (2.1)</a></span>] may be associated with increased incidence and severity of adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4.	Arthus Reactions</h2>
<p class="First">Persons who experienced an Arthus-type <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> following a prior dose of a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>-toxoid containing vaccine usually have high serum <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin levels and should not receive DECAVAC vaccine more frequently than every 10 years, even for <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> prophylaxis as part of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> management [see<span class="Italics"><a href="#S2.1"> Dosage and Administration (2.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5. Guillain-Barré Syndrome and Brachial <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">Neuritis</span></h2>
<p class="First">A review by the Institute of Medicine found evidence for a causal relation between <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid and both brachial <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span> and Guillain-Barré syndrome. (3) If Guillain-Barré syndrome occurred within 6 weeks after receipt of a prior vaccine containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid, the risk for Guillain-Barré syndrome may be increased following DECAVAC vaccine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6.	Limitations of Vaccine Effectiveness</h2>
<p class="First">Vaccination with DECAVAC vaccine may not protect all individuals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7.	Altered Immunocompetence</h2>
<p class="First">Immune responses to inactivated vaccines and toxoids when given to immunocompromised persons may be suboptimal. The immune response to DECAVAC vaccine administered to immunocompromised individuals (whether from disease or treatment) has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6.	ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1.	Data from Clinical Studies</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to vaccine use and for approximating rates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2.	Primary Immunization</h2>
<p class="First">In a clinical study, 42 persons 6-58 years of age underwent primary immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span>. Eight of these participants (19%) noted local reactions consisting of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> at the injection site; none reported systemic symptoms. (4)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3.	Booster Immunization</h2>
<p class="First">In a clinical study, 792 adolescents 11-17 years of age and 573 adults 18-64 years of age received a booster dose with DECAVAC vaccine. Study participants had not received <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> or <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid-containing vaccines within the previous 5 years. Solicited local reactions and systemic adverse events were monitored daily for 14 days post-vaccination using subject diary cards. Serious adverse events were monitored through 6 months post-vaccination. Ninety-seven percent of participants who received DECAVAC vaccine completed the 6-month telephone follow-up.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3.1"></a><p></p>
<p class="First"><span class="Bold">Solicited Adverse Events</span></p>
<p>The frequency of selected solicited <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>) occurring during Days 0-14 following booster vaccination with DECAVAC vaccine in adolescents 11 through 17 years of age, and adults 18 through 64 years of age are presented in Table 2. <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> at the injection site was the most common adverse reaction occurring in 71% of adolescents and 62.9% of adults.</p>
<a name="table2"></a><table width="80%">
<caption><span>Table 2: Frequencies of Solicited <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reactions</span> for Adolescents and Adults, Days 0-14 Following BoosterVaccination with DECAVAC Vaccine</span></caption>
<col align="left" valign="middle" width="15%">
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" colspan="2">Adverse Event</th>
<th class="Rrule" align="center">Adolescents<br>11-17 years<br>N<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> = 783-787 (%)</th>
<th class="Rrule" align="center">Adults<br>18-64 years<br>N<a href="#footnote-5" class="Sup">*</a> = 551-561 (%)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>N = number of participants who provided data (not all participants evaluated every event).</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Interfered with activities, but did not necessitate medical care or absenteeism.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">‡</a></dt>
<dd>Incapacitating, prevented the performance of usual activities, may have/or did necessitate medical care or absenteeism.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" rowspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection Site Pain</span></span></td>
<td class="Rrule" align="left"><span class="Bold">Any</span></td>
<td class="Rrule" align="center">71.0</td>
<td class="Rrule" align="center">62.9</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold">Moderate<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a></span></td>
<td class="Rrule" align="center">15.6</td>
<td class="Rrule" align="center">10.2</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold">Severe<a name="footnote-reference-7" href="#footnote-7" class="Sup">‡</a></span></td>
<td class="Rrule" align="center">0.6</td>
<td class="Rrule" align="center">0.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="6"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4319319" conceptname="Injection site edema">Injection Site Swelling</span></span></td>
<td class="Rrule" align="left"><span class="Bold">Any</span></td>
<td class="Rrule" align="center">18.3</td>
<td class="Rrule" align="center">17.3</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold">Moderate
														</span></td>
<td class="Rrule" align="left" colspan="2"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold">  1.0 to 3.4 cm</span></td>
<td class="Rrule" align="center">5.7</td>
<td class="Rrule" align="center">5.4</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold">Severe
														</span></td>
<td class="Rrule" align="left" colspan="2"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold">  ≥3.5 cm</span></td>
<td class="Rrule" align="center">5.5</td>
<td class="Rrule" align="center">5.5</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold">  ≥5 cm </span></td>
<td class="Rrule" align="center">3.6</td>
<td class="Rrule" align="center">2.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="6"><span class="Bold">Injection Site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></span></td>
<td class="Rrule" align="left"><span class="Bold">Any</span></td>
<td class="Rrule" align="center">19.7</td>
<td class="Rrule" align="center">21.6</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold">Moderate
														</span></td>
<td class="Rrule" align="left" colspan="2"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold">  1.0 to 3.4 cm</span></td>
<td class="Rrule" align="center">4.6</td>
<td class="Rrule" align="center">8.4</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold">Severe
														</span></td>
<td class="Rrule" align="left" colspan="2"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold">  ≥3.5 cm</span></td>
<td class="Rrule" align="center">5.3</td>
<td class="Rrule" align="center">4.8</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left"><span class="Bold">  ≥5 cm </span></td>
<td class="Rrule" align="center">2.9</td>
<td class="Rrule" align="center">3.0</td>
</tr>
</tbody>
</table>
<p>The frequency of solicited systemic adverse events occurring during Days 0-14 following booster vaccination with DECAVAC vaccine are presented in Table 3. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> was the most frequent solicited systemic adverse event, and was usually of mild or moderate intensity.</p>
<a name="table3"></a><table width="85%">
<caption><span>Table 3:	Frequencies of Solicited Systemic Adverse Events for Adolescents and Adults, Days 0-14 Following Booster Vaccination with DECAVAC Vaccine</span></caption>
<col align="left" valign="middle" width="15%">
<col align="left" valign="middle" width="29%">
<col align="center" valign="middle" width="31%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" colspan="2" rowspan="2">Adverse Event</th>
<th class="Botrule Rrule" align="center">Adolescents 11-17 years</th>
<th class="Botrule Rrule" align="center" colspan="2">Adults 18-64 years</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="center">N<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a> = 787 (%)</th>
<th class="Rrule" align="center" colspan="2">N<a href="#footnote-8" class="Sup">*</a> = 560-561 (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>N = number of participants who provided data (not all participants evaluated every event).</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>Interfered with activities, but did not necessitate medical care or absenteeism.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">‡</a></dt>
<dd>Incapacitating, prevented the performance of usual activities, may have/or did necessitate medical care or absenteeism.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" rowspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></td>
<td class="Rrule" align="left"><span class="Bold">Any</span></td>
<td class="Rrule" align="center">40.4</td>
<td class="Rrule" align="center" colspan="2">34.1</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Moderate</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">11.1</td>
<td class="Rrule" align="center" colspan="2">10.5</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Severe</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">1.5</td>
<td class="Rrule" align="center" colspan="2">2.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3"><span class="Bold">Body <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Ache</span> or Muscle<br><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span> </span></td>
<td class="Rrule" align="left"><span class="Bold">Any</span></td>
<td class="Rrule" align="center">29.9</td>
<td class="Rrule" align="center" colspan="2">18.8</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Moderate</span><a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">6.9</td>
<td class="Rrule" align="center" colspan="2">5.7</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Severe</span><a href="#footnote-10" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.9</td>
<td class="Rrule" align="center" colspan="2">0.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Tiredness</span></span></td>
<td class="Rrule" align="left"><span class="Bold">Any</span></td>
<td class="Rrule" align="center">27.3</td>
<td class="Rrule" align="center" colspan="2">20.7</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Moderate</span><a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">7.5</td>
<td class="Rrule" align="center" colspan="2">6.1</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Severe</span><a href="#footnote-10" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">1.0</td>
<td class="Rrule" align="center" colspan="2">0.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></span></td>
<td class="Rrule" align="left"><span class="Bold">Any</span></td>
<td class="Rrule" align="center">12.6</td>
<td class="Rrule" align="center" colspan="2">6.6</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Moderate</span><a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">2.5</td>
<td class="Rrule" align="center" colspan="2">1.6</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Severe</span><a href="#footnote-10" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.1</td>
<td class="Rrule" align="center" colspan="2">0.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span></td>
<td class="Rrule" align="left"><span class="Bold">Any</span></td>
<td class="Rrule" align="center">12.3</td>
<td class="Rrule" align="center" colspan="2">7.9</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Moderate</span><a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">3.2</td>
<td class="Rrule" align="center" colspan="2">1.8</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Severe</span><a href="#footnote-10" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.6</td>
<td class="Rrule" align="center" colspan="2">0.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3"><span class="Bold">Sore and<br>Swollen<br>Joints</span></td>
<td class="Rrule" align="left"><span class="Bold">Any</span></td>
<td class="Rrule" align="center">11.7</td>
<td class="Rrule" align="center" colspan="2">7.0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Moderate</span><a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">2.5</td>
<td class="Rrule" align="center" colspan="2">2.1</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Severe</span><a href="#footnote-10" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.1</td>
<td class="Rrule" align="center" colspan="2">0.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></td>
<td class="Rrule" align="left"><span class="Bold">Any</span></td>
<td class="Rrule" align="center">10.2</td>
<td class="Rrule" align="center" colspan="2">11.3</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Moderate</span><a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">2.0</td>
<td class="Rrule" align="center" colspan="2">2.7</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Severe</span><a href="#footnote-10" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.0</td>
<td class="Rrule" align="center" colspan="2">0.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3"><span class="Bold">Lymph<br>Node<br><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span></span></td>
<td class="Rrule" align="left"><span class="Bold">Any</span></td>
<td class="Rrule" align="center">5.3</td>
<td class="Rrule" align="center" colspan="2">4.1</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Moderate</span><a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">0.5</td>
<td class="Rrule" align="center" colspan="2">0.5</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Severe</span><a href="#footnote-10" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.0</td>
<td class="Rrule" align="center" colspan="2">0.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></td>
<td class="Rrule" align="left"><span class="Bold">Any</span></td>
<td class="Rrule" align="center">2.8</td>
<td class="Rrule" align="center" colspan="2">1.8</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Moderate</span><a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">1.1</td>
<td class="Rrule" align="center" colspan="2">0.9</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Severe</span><a href="#footnote-10" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.3</td>
<td class="Rrule" align="center" colspan="2">0.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></span></td>
<td class="Rrule" align="left"><span class="Bold">Any ≥38.0°C (≥100.4°F)</span></td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center" colspan="2">1.1</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold">≥38.8°C to ≤39.4°C<br>(≥102.0°F to ≤103.0°F)</span></td>
<td class="Rrule" align="center">0.6</td>
<td class="Rrule" align="center" colspan="2">0.2</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold">≥39.5°C (≥103.1°F)</span></td>
<td class="Rrule" align="center">0.1</td>
<td class="Rrule" align="center" colspan="2">0.2</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></span></td>
<td class="Rrule" align="left"><span class="Bold">Any</span></td>
<td class="Rrule" align="center">2.0</td>
<td class="Rrule" align="center">2.3</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3.2"></a><p></p>
<p class="First"><span class="Bold">Serious Adverse Events</span></p>
<p>Among 792 adolescents 11-17 years of age and 573 adults 18-64 years of age who received a booster dose with DECAVAC vaccine, 2 adolescents and 2 adults reported a serious adverse event that occurred within 30 days following vaccination. Events reported in adolescents were jaw <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> secondary to <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>/appendectomy. Events reported in adults were <span class="product-label-link" type="condition" conceptid="4289309" conceptname="Atrial septal defect">atrial septal defect</span> and elective surgical repair in one subject, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in one subject with a history of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.4"></a><a name="section-6.4"></a><p></p>
<h2>6.4.	Post-Marketing Experience</h2>
<p class="First">The following adverse events have been spontaneously reported during the post-marketing use of Td manufactured by Sanofi Pasteur Inc. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccination. The following adverse events were included based on severity, frequency of reporting or the strength of causal association with DECAVAC vaccine.</p>
<ul class="Disc"><li>
<span class="Italics">Blood and Lymphatic System Disorders</span><br><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span>.</li></ul>
<ul class="Disc"><li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> (such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>), including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.</li></ul>
<ul class="Disc"><li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</li></ul>
<ul class="Disc"><li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </li></ul>
<ul class="Disc"><li>
<span class="Italics">Musculoskeletal, Connective Tissue and <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">Bone Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in extremities, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">musculoskeletal stiffness</span>.</li></ul>
<ul class="Disc"><li>
<span class="Italics">General Disorders and Administration Site Conditions</span><br><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span> (including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, warmth, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, and <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>).<br><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>.</li></ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7.	DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1.	Concomitant Administration with Other Vaccines</h2>
<p class="First">No safety and immunogenicity data are available regarding concomitant administration of DECAVAC vaccine with other US licensed vaccines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2.	Immunosuppressive Treatments</h2>
<p class="First">Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to DECAVAC vaccine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3.	<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Immune Globulin (Human)</h2>
<p class="First">If passive protection against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> is required, TIG (Human) may be administered according to its prescribing information, concomitantly with DECAVAC vaccine at a separate site with a separate needle and syringe. [See<span class="Italics"><a href="#S2.1"> Dosage and Administration (2.1)</a>.</span>]</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8.	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1.	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Catergory C: Animal reproduction studies have not been conducted with DECAVAC vaccine. It is also not known whether DECAVAC vaccine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. DECAVAC vaccine should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3.	Nursing Mothers</h2>
<p class="First">It is not known whether DECAVAC vaccine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DECAVAC vaccine is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4.	Pediatric Use</h2>
<p class="First">DECAVAC vaccine is not approved for use in infants and children younger than 7 years of age. Safety and effectiveness of DECAVAC vaccine in this age group have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5.	Geriatric Use</h2>
<p class="First">Clinical studies of DECAVAC vaccine did not include subjects aged 65 years and over to determine whether they respond differently than younger subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-9"></a><p></p>
<h1>11.	DESCRIPTION</h1>
<p class="First">DECAVAC vaccine, <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoids Adsorbed, for intramuscular injection, is a sterile suspension of alum (aluminum potassium sulfate)-precipitated toxoids in an isotonic sodium chloride solution. The vaccine, after <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, is a turbid liquid, whitish-gray in color.</p>
<p><span class="Italics">Corynebacterium diphtheriae</span> cultures are grown in a modified Mueller and Miller medium. (5) <span class="Italics">Clostridium tetani</span> cultures are grown in a peptone-based medium containing an extract of bovine muscle tissue. The bovine muscle tissue used in this medium is US sourced. <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxins produced during the growth of the cultures are detoxified with formaldehyde. The detoxified materials are then separately purified by serial ammonium sulfate fractionation and diafiltration, and adsorbed onto alum.</p>
<p>Each 0.5 mL dose of DECAVAC vaccine is formulated to contain the following active ingredients: 5 Lf of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid and 2 Lf of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid. The <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoids induce at least 2 units and 0.5 units of antitoxin per mL of serum, respectively, in the guinea pig potency test. Each 0.5 mL dose also contains a trace amount of thimerosal [mercury derivative, (≤0.3 mcg mercury/dose) not as a preservative] from the manufacturing process, aluminum potassium sulfate adjuvant (not more than 0.28 mg aluminum by assay), and not more than 100 mcg (0.02%) of residual formaldehyde.</p>
<p>The tip caps of the prefilled syringes may contain natural rubber latex. No other components of any presentation contain latex.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-10"></a><p></p>
<h1>12.	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.1"></a><a name="section-10.1"></a><p></p>
<h2>12.1.	<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> is an acute and often fatal disease caused by an extremely potent neurotoxin produced by <span class="Italics">C tetani</span>. Protection against disease is due to the development of neutralizing antibodies to <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxin. A serum <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin level of 0.01 IU/mL, measured by neutralization assays, is considered the minimum protective level. (6) (7) A <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxoid level ≥0.1 IU/mL as measured by the enzyme-linked immunosorbent assay (ELISA) used in the booster immunization study of DECAVAC vaccine is considered protective [see<span class="Italics"><a href="#S14.2"> Clinical Studies (14.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.2"></a><a name="section-10.2"></a><p></p>
<h2>12.2.	<span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> is an acute toxin-mediated disease caused by toxigenic <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C diphtheriae. </span>Protection against disease is due to the development of neutralizing antibodies to <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxin. A serum <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> antitoxin level of 0.01 IU/mL is the lowest level giving some degree of protection. (7) (8) A <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> antitoxin level of 0.1 IU/mL is generally regarded as protective. (8) <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> antitoxin levels of ≥1.0 IU/mL have been associated with long-term protection. (8) Antibodies to <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxin were measured by a microneutralization assay in the booster immunization study of DECAVAC vaccine [see <span class="Italics"><a href="#S14.2">Clinical Studies (14.2)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-11"></a><p></p>
<h1>13.	NON-CLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-11.1"></a><p></p>
<h2>13.1.	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No studies have been performed with DECAVAC vaccine to evaluate carcinogenicity, mutagenic potential, or impact on fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-12"></a><p></p>
<h1>14.	CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-12.1"></a><p></p>
<h2>14.1.	Primary Immunization</h2>
<p class="First">The effectiveness of primary immunization with <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid used in DECAVAC vaccine was determined on the basis of an immunogenicity study, with a comparison to a serological correlate of protection (0.01 antitoxin units/mL) established by the Panel on Review of Bacterial Vaccines &amp; Toxoids. (7) A clinical study to evaluate the serological responses was performed in 58 individuals 6-58 years of age. Of these, 46 persons had no evidence of prior immunity to <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxin and 47 persons had no evidence of prior immunity to <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxin. The results indicated protective levels of antibody were achieved in greater than 90% of the study population after primary immunization with both components. (4)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-12.2"></a><p></p>
<h2>14.2.	Booster Immunization</h2>
<p class="First">In a clinical study, the immune response to booster immunization with DECAVAC vaccine was evaluated in 516 adolescents 11-17 years of age and 509 adults 18-64 years of age. Participants had not received a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> or <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid-containing vaccine within the previous 5 years. Sera were obtained before and approximately 35 days after vaccination. Antibodies to <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid were measured by an ELISA. Antibodies to <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxin were measured by a microneutralization assay. Seroprotection rates and booster response rates for <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> are provided in Table 4. Seroprotection rates and booster response rates for <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> are provided in Table 5.</p>
<a name="table4"></a><table width="100%">
<caption><span>Table 4: Pre-vaccination and Post-vaccination <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Seroprotection Rates and Booster Response Rates Following a Booster Dose of DECAVAC Vaccine in Adolescents and Adults 11 Through 64 Years of Age</span></caption>
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" colspan="2" rowspan="2"></th>
<th class="Rrule" align="center" colspan="5"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Antitoxoid (IU/mL)</th>
</tr>
<tr class="Botrule">
<th class="Rrule" align="center" colspan="2">Pre-Vaccination</th>
<th class="Rrule" align="center" colspan="3">1 Month Post-Vaccination</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Age Group<br>(years)</th>
<th class="Rrule" align="center">N<a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a>
</th>
<th class="Rrule" align="center">% ≥0.1<a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a><br>(95% CI)</th>
<th class="Rrule" align="center">% ≥1.0<a name="footnote-reference-13" href="#footnote-13" class="Sup">‡</a><br>(95% CI)</th>
<th class="Rrule" align="center">% ≥0.1<a href="#footnote-12" class="Sup">†</a><br>(95% CI)</th>
<th class="Rrule" align="center">% ≥1.0<a href="#footnote-13" class="Sup">‡</a><br>(95% CI)</th>
<th class="Rrule" align="center">% Booster<a name="footnote-reference-14" href="#footnote-14" class="Sup">§</a><br>(95% CI)</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>N = number of participants in the per-protocol population with available data.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>With the ELISA used in this study, a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxoid level of 0.1 IU/mL is considered the protective level.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">‡</a></dt>
<dd>With the ELISA used in this study, a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxoid level of 1.0 IU/mL is 10 times the protective level. </dd>
<dt><a name="footnote-14" href="#footnote-reference-14">§</a></dt>
<dd>Booster response is defined as: A four-fold rise in antibody concentration, if the pre-vaccination concentration was equal to or below the cut-off value and a two-fold rise in antibody concentration if the pre-vaccination concentration was above the cut-off value. The cut-off value for <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> was 2.7 IU/mL.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"><span class="Bold">11-17</span></td>
<td class="Rrule" align="center"><span class="Bold">516</span></td>
<td class="Rrule" align="center">99.2<br>(98.0, 99.8)</td>
<td class="Rrule" align="center">43.8<br>(39.5, 48.2)</td>
<td class="Rrule" align="center">100.0<br>(99.3, 100.0)</td>
<td class="Rrule" align="center">99.4<br>(98.3, 99.9)</td>
<td class="Rrule" align="center">91.3<br>(88.5, 93.6)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"><span class="Bold">18-64</span></td>
<td class="Rrule" align="center"><span class="Bold">509</span></td>
<td class="Rrule" align="center">95.9<br>(93.8, 97.4)</td>
<td class="Rrule" align="center">70.3<br>(66.2, 74.3)</td>
<td class="Rrule" align="center">99.8<br>(98.9, 100.0)</td>
<td class="Rrule" align="center">98.2<br>(96.7, 99.2)</td>
<td class="Rrule" align="center">66.8<br>(62.5, 70.9)</td>
</tr>
</tbody>
</table>
<a name="table5"></a><table width="100%">
<caption><span>Table 5: Pre-vaccination and Post-vaccination <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Seroprotection Rates and Booster Response Rates Following a Booster Dose of DECAVAC Vaccine in Adolescents and Adults 11 Through 64 Years of Age</span></caption>
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" colspan="2" rowspan="2"></th>
<th class="Rrule" align="center" colspan="5"><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span>  Antitoxin (IU/mL)</th>
</tr>
<tr class="Botrule">
<th class="Rrule" align="center" colspan="2">Pre-Vaccination</th>
<th class="Rrule" align="center" colspan="3">1 Month Post-Vaccination</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Age Group<br>(years)</th>
<th class="Rrule" align="center">N<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a>
</th>
<th class="Rrule" align="center">% ≥0.1<a name="footnote-reference-16" href="#footnote-16" class="Sup">†</a><br>(95% CI)</th>
<th class="Rrule" align="center">% ≥1.0<a name="footnote-reference-17" href="#footnote-17" class="Sup">‡</a><br>(95% CI)</th>
<th class="Rrule" align="center">% ≥0.1<a href="#footnote-16" class="Sup">†</a><br>(95% CI)</th>
<th class="Rrule" align="center">% ≥1.0<a href="#footnote-17" class="Sup">‡</a><br>(95% CI)</th>
<th class="Rrule" align="center">% Booster<a name="footnote-reference-18" href="#footnote-18" class="Sup">§</a><br>(95% CI)</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>N = number of participants in the per-protocol population with available data.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">†</a></dt>
<dd>With the microneutralization assay used in this study, a <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> antitoxin level of 0.1 IU/mL is generally regarded as protective.</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">‡</a></dt>
<dd>With the microneutralization assay used in this study, <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> antitoxin levels ≥1.0 IU/mL have been associated with long term protection.</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">§</a></dt>
<dd>Booster response is defined as: A four-fold rise in antibody concentration, if the pre-vaccination concentration was equal to or below the cut-off value and a two-fold rise in antibody concentration if the pre-vaccination concentration was above the cut-off value. The cut-off value for <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> was 2.56 IU/mL.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"><span class="Bold">11-17</span></td>
<td class="Rrule" align="center"><span class="Bold">515-516</span></td>
<td class="Rrule" align="center">70.7<br>(66.5, 74.6)</td>
<td class="Rrule" align="center">17.3<br>(14.1, 20.8)</td>
<td class="Rrule" align="center">99.8<br>(98.9, 100.0)</td>
<td class="Rrule" align="center">98.4<br>(97.0, 99.3)</td>
<td class="Rrule" align="center">95.0<br>(92.7, 96.7)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"><span class="Bold">18-64</span></td>
<td class="Rrule" align="center"><span class="Bold">506-507</span></td>
<td class="Rrule" align="center">63.3<br>(59.0, 67.5)</td>
<td class="Rrule" align="center">16.0<br>(12.9, 19.5)</td>
<td class="Rrule" align="center">95.1<br>(92.8, 96.8)</td>
<td class="Rrule" align="center">79.9<br>(76.1, 83.3)</td>
<td class="Rrule" align="center">83.4<br>(79.9, 86.5)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-13"></a><p></p>
<h1>15.	REFERENCES</h1>
<dl>
<dt>1</dt>
<dd>CDC. General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60(RR-02):1-60.</dd>
<dt>2</dt>
<dd>CDC. <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span>, <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>, and <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span>: recommendations for vaccine use and other preventive measures: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991:40(No. RR-10):1-28.</dd>
<dt>3</dt>
<dd>Institute of Medicine (US). Stratton KR, et al, eds. Adverse events associated with childhood vaccines: evidence bearing on causality. Washington (DC): National Academy Press. 1994:67-117.</dd>
<dt>4</dt>
<dd>Myers MG, et al. Primary immunization with <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoids. JAMA 248:1982;2478-2480.</dd>
<dt>5</dt>
<dd>Mueller JH, et al. Production of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxin of high potency (100 Lf) on a reproducible medium. J Immunol 40:1941;21-32.</dd>
<dt>6</dt>
<dd>Wassilak SGF, et al. <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> toxoid. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. Philadelphia, PA: WB Saunders Company;2008:805-839.</dd>
<dt>7</dt>
<dd>Department of Health and Human Services, Food and Drug Administration. Biological Products; Bacterial Vaccines and Toxoids; Implementation of Efficacy Review; Proposed Rule. Federal Register Vol 50 No 240:1985; 51002-51117.</dd>
<dt>8</dt>
<dd>Vitek CR and Wharton M. <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> toxoid. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. Philadelphia, PA: WB Saunders Company;2008:139-156.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16.	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.1"></a><a name="section-14.1"></a><p></p>
<h2>16.1.	How Supplied</h2>
<p class="First">Vial, 1 Dose (10 per package) – NDC 49281-291-83. Contains no latex.</p>
<p>Syringe, 1 Dose (10 per package, without needle) – NDC 49281-291-10. The tip caps of the prefilled syringes may contain natural rubber latex. No other components contain latex.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="S16.2"></a><a name="section-14.2"></a><p></p>
<h2>16.2.	Storage and Handling</h2>
<p class="First">Store at 2° to 8°C (35° to 46°F). Do not freeze.</p>
<p>Do not use vaccine after expiration date.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17.	PATIENT COUNSELING INFORMATION</h1>
<p class="First">Prior to administration of DECAVAC vaccine, health-care providers should inform the patient, parent, or guardian of the benefits and risks of immunization and of the importance of completing the primary immunization series or receiving recommended booster doses, as appropriate.</p>
<p>The health-care provider should inform the patient, parent, or guardian about the potential for adverse reactions that have been temporally associated with the administration of DECAVAC vaccine or other vaccines containing similar ingredients. Patients, parents or guardians should be instructed to report any suspected adverse reactions to their health-care provider.</p>
<p>The health-care provider should provide the Vaccine Information Statements which are required by the National Childhood Vaccine Injury Act of 1986 to be given with each immunization.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Product information<br>as of March 2011.</p>
<p>Manufactured by:<br><span class="Bold">Sanofi Pasteur Inc.</span><br>Swiftwater PA 18370 USA<br>5876-5877</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 0.5 mL Syringe Carton</span></p>
<p>NDC <span class="Bold">49281-291-10</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> and<br><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span><br>Toxoids<br>Adsorbed</span></p>
<p><span class="Bold">DECAVAC<span class="Sup">®</span></span></p>
<p><span class="Bold">For 7 years of age and older</span></p>
<p><span class="Bold">Td</span></p>
<p><span class="Bold">10</span> Prefilled<br>Syringes<br><span class="Bold">0.5 mL</span> each</p>
<p><span class="Italics">Rx only</span></p>
<p><span class="Bold">sanofi pasteur</span></p>
<div class="Figure"><img alt="Principal Display Panel - 0.5 mL Syringe Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7faec1c-046f-45c9-b9c0-ef65d377ba87&amp;name=decavac-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 0.5 mL Vial Label</span></p>
<p>NDC<span class="Bold"> 49281-291-10</span></p>
<p><span class="Bold">0.5 mL </span>Dose<br><span class="Italics">Rx only</span><br><span class="Bold">Td</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span><br>Toxoids Absorbed</span></p>
<p><span class="Bold">DECAVAC</span><span class="Sup">®</span></p>
<p><span class="Bold">IM only</span></p>
<p>For 7 years of age and older<br>Mfd by:<span class="Bold"> Sanofi Pasteur Inc.</span></p>
<div class="Figure"><img alt="Principal Display Panel - 0.5 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7faec1c-046f-45c9-b9c0-ef65d377ba87&amp;name=decavac-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DECAVAC 		
					</strong><br><span class="contentTableReg">clostridium tetani toxoid antigen (formaldehyde inactivated) and corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">VACCINE LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49281-291</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</strong> (CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)) </td>
<td class="formItem">CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</td>
<td class="formItem">5 [Lf]  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</strong> (CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)) </td>
<td class="formItem">CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</td>
<td class="formItem">2 [Lf]  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49281-291-83</td>
<td class="formItem">10  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.5 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49281-291-10</td>
<td class="formItem">10  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">0.5 mL in 1 SYRINGE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103921</td>
<td class="formItem">03/24/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sanofi Pasteur Inc.
							(086723285)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Pasteur Inc.</td>
<td class="formItem"></td>
<td class="formItem">086723285</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>704e0b02-2648-470f-9598-91257dd31444</div>
<div>Set id: f7faec1c-046f-45c9-b9c0-ef65d377ba87</div>
<div>Version: 2</div>
<div>Effective Time: 20110318</div>
</div>
</div> <div class="DistributorName">Sanofi Pasteur Inc.</div></p>
</body></html>
